NCT06213974 A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
| NCT ID | NCT06213974 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Cytomegalovirus (CMV) |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-09-03 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2024-09-03 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of this study is to learn about the safety of Maribavir in adults and children with post-transplant CMV infection in routine clinical practice in Argentina. The other aim is to study the effectiveness of the treatment with Maribavir in routine clinical practice in Argentina. Participants will be treated by their doctors according to normal medical practice. Study data will be collected either from information already available in the medical records or during study conduct.
Eligibility Criteria
Inclusion Criteria: * Adult participants (18 years or older) and pediatric participants (12 years of age and older and weighing at least 35 kilogram \[kg\]) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in the real-world setting of common clinical practice in Argentina. * Have received at least one dose of maribavir according to approved indications. * Have signed the mandatory informed consent/assent that has been agreed with national regulatory authorities (ANMAT) as applicable. Exclusion Criteria \- There are no specific exclusion criteria.
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT06213974 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Cytomegalovirus (CMV). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06213974 currently recruiting?
Yes, NCT06213974 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT06213974 trial being conducted?
This trial is being conducted at City of Buenos Aires, Argentina.
Who is sponsoring the NCT06213974 clinical trial?
NCT06213974 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 10 participants.